Jounce Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 128
Employees
  • Stock Symbol
  • JNCE
Stock Symbol
  • Share Price
  • $7.79
  • (As of Friday Closing)

Jounce Therapeutics General Information

Description

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company have developed a suite of integrated technologies that comprise Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 780 Memorial Drive
  • Cambridge, MA 02138
  • United States
+1 (857) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Jounce Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.79 $7.85 $5.03 - $14.84 $402M 51.2M 460K -$0.46

Jounce Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 106,891 192,355 134,740 (101,558)
Revenue 89,246 62,339 147,872 65,201
EBITDA (16,865) (40,427) 60,720 (23,502)
Net Income (19,977) (43,842) 56,823 (27,379)
Total Assets 306,160 244,236 205,882 214,452
Total Debt 15,335 16,889 19,790 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jounce Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jounce Therapeutics‘s full profile, request access.

Request a free trial

Jounce Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Jounce Therapeutics‘s full profile, request access.

Request a free trial

Jounce Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the
Biotechnology
Cambridge, MA
128 As of 2020
00000
000000 - 000 00000

00000000

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000 000000000
San Carlos, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000000

ctetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim a
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jounce Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexigen Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 Private Equity-Backed Holliston, MA 00 000.00 000000000 - 000.00
To view Jounce Therapeutics’s complete competitors history, request access »

Jounce Therapeutics Executive Team (21)

Name Title Board Seat Contact Info
Richard Murray Ph.D Chief Executive Officer & Board Member
Kimberlee Drapkin Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Stephen Farrand Ph.D Chief Technology Officer
Dmitri Wiederschain Ph.D Chief Scientific Officer
Jennifer Michaelson Ph.D Executive Program Leader & Senior Director of Pharmacology and Preclinical Development
You’re viewing 5 of 21 executive team members. Get the full list »

Jounce Therapeutics Board Members (9)

Name Representing Role Since
Barbara Duncan Self Board Member 000 0000
Cary Pfeffer MD Third Rock Ventures Board Member 000 0000
Higgons Duncan Jounce Therapeutics Board Member 000 0000
Luisa Salter-Cid Ph.D Jounce Therapeutics Board Member 000 0000
Perry Karsen Third Rock Ventures Chairman & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Jounce Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jounce Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Jounce Therapeutics‘s full profile, request access.

Request a free trial